背景:硫酸镁是治疗子痫和先兆子痫患者最常用的抗惊厥药。这项研究的目的是确定硫酸镁的12小时方案在治疗轻度或重度先兆子痫和子痫患者的疗效和安全性方面是否超过24小时方案。
方法:我们搜索了六个电子数据库:PubMed,Scopus,WebofScience,科克伦图书馆,奥维德,谷歌学者。进行此搜索是为了得出直到2023年1月15日发表的任何研究。我们通过ReviewManagerSoftware版本5.4进行了统计分析计划。
结果:我们纳入了13项随机对照试验,共2813例患者。我们的荟萃分析显示,硫酸镁组的12小时方案和硫酸镁组的24小时方案在我们感兴趣的结果中没有统计学上的显着差异:癫痫发作的发生(RD:-0.00,95%CI[-0.01,0.00],P=0.56),深肌腱反射减弱(RD:-0.00,95%CI[-0.01,0.01],P=0.80),呼吸抑制(RD:-0.00,95%CI[-0.02,0.01],P=0.57),和肺水肿(RD:-0.00,95%CI[-0.01,0.01],P=0.85)。
结论:我们的研究表明,12小时和24小时治疗方案的有效性和毒性风险没有统计学上的显著差异。
BACKGROUND: Magnesium sulfate is the most utilized anticonvulsant for treating patients with eclampsia and pre-eclampsia. The purpose of this study is to determine whether the 12-h regimen of magnesium sulfate outweighs the 24-h regimen in both efficacy and safety in the management of patients with mild or severe pre-eclampsia and eclampsia.
METHODS: We searched six electronic databases: PubMed, Scopus, Web of Science, Cochrane Library, Ovid, and Google Scholar. This search was conducted to yield any studies that were published until 15 January 2023. We did the statistical analysis plan by Review Manager Software version 5.4.
RESULTS: We included 13 randomized control trials with 2813 patients in this systematic review. Our meta-analysis revealed that there were no statistically significant differences between the 12-h regimen of the magnesium sulfate group and the 24-h regimen of the magnesium sulfate group in our outcome of interest: occurrence of seizure (RD: -0.00, 95% CI [-0.01, 0.00], P = 0.56), diminished deep tendon reflexes (RD: -0.00, 95% CI [-0.01, 0.01], P = 0.80), respiratory depression (RD: -0.00, 95% CI [-0.02, 0.01], P = 0.57), and pulmonary edema (RD: -0.00, 95% CI [-0.01, 0.01], P = 0.85).
CONCLUSIONS: Our study showed no statistically significant difference in effectiveness and toxicity risk between the 12-h and 24-h regimens.